Literature DB >> 6547969

Serum tissue polypeptide antigen (TPA) in thyroid cancer.

E Martino, G Bambini, F Aghini-Lombardi, E Motz, F Pacini, R Lari, L Baschieri, A Pinchera.   

Abstract

Serum tissue polypeptide antigen, (TPA), carcinoembryonic antigen (CEA), calcitonin (CT) and thyroglobulin (Tg) have been measured by specific radioimmunoassays in 174 patients with various types of thyroid cancer previously submitted to thyroidectomy. Elevated serum TPA concentrations were found in 12 of 13 patients with local invasion or distant metastases from undifferentiated thyroid cancer or thyroid lymphosarcoma, while serum Tg and CEA values were normal or undetectable. In 123 patients with well differentiated thyroid cancer serum TPA was usually normal regardless of the presence or absence of functioning metastases. On the contrary, 14 of 15 patients with "dedifferentiated" metastases from previously differentiated thyroid cancer had elevated serum TPA values, while serum CEA was normal and serum Tg variable. Serum CT was confirmed as the most sensitive marker of metastatic medullary thyroid carcinoma, but elevated serum TPA values were also found in most of these cases. The present data indicate that serum TPA provides a new humoral marker in the follow-up of undifferentiated and "dedifferentiated" thyroid carcinoma and may also be usefully employed as an additional marker for medullary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547969     DOI: 10.1007/BF03348433

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

1.  Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique; presence of an insoluble, heat-labile tumor antigen.

Authors:  B BJORKLUND; V BJORKLUND
Journal:  Int Arch Allergy Appl Immunol       Date:  1957

2.  Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma.

Authors:  R A DeLellis; A H Rule; I Spiler; L Nathanson; A H Tashjian; H J Wolfe
Journal:  Am J Clin Pathol       Date:  1978-10       Impact factor: 2.493

3.  Evaluation of a solid-phase immunoradiometric assay (IRMA) for serum thyroglobulin: effect of anti-thyroglobulin autoantibody.

Authors:  S Mariotti; C Cupini; C Giani; R Lari; E Rolleri; A Falco; M Marchisio; A Pinchera
Journal:  Clin Chim Acta       Date:  1982-08-18       Impact factor: 3.786

4.  Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy).

Authors:  F Pacini; A Pinchera; C Giani; L Grasso; L Baschieri
Journal:  Clin Endocrinol (Oxf)       Date:  1980-07       Impact factor: 3.478

5.  Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.

Authors:  A J Herle; R P Uller
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

6.  A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasms.

Authors:  C J Menendez-Botet; H F Oettgen; C M Pinsky; M K Schwartz
Journal:  Clin Chem       Date:  1978-06       Impact factor: 8.327

7.  Specificity and basis of the tissue polypeptide antigen.

Authors:  B Björklund; V Björklund
Journal:  Cancer Detect Prev       Date:  1983

8.  Chemical studies of tissue polypeptide antigen (TPA). III. on the nature of the antigenic determinant(s) of TPA subfraction B1.

Authors:  B Wiklund; B Lüning; B Björklund
Journal:  Acta Chem Scand B       Date:  1981

9.  Determination of TPA levels in breast cancer and controls.

Authors:  K Mross; B Mross; D I Wolfrum; H Rauschecker
Journal:  Klin Wochenschr       Date:  1983-05-02

10.  CEA and non-specific cross-reacting antigen (NCA) in medullary carcinomas of the thyroid.

Authors:  P Burtin; C Calmettes; M C Fondaneche
Journal:  Int J Cancer       Date:  1979-06-15       Impact factor: 7.396

View more
  1 in total

Review 1.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.